CNTX
Context TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
CTIM-76 has produced early activity in heavily pretreated platinum-resistant ovarian cancer, including confirmed responses, disease control, durability in early responders, and a relatively favorable early CRS profile. Q3W exploration and additional pipeline data could broaden the investment case.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Additional capital is expected to be needed, creating financing and dilution risk.
Momentum
99
Value
41
Sentiment
55
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.65 · Bull $1.20 · Bear $0.30
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $5.44
Why
Momentum99 · Δ7d -
Value41 · Δ7d -0.1
Sentiment55 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
99
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-17.8
Sentiment
55
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 99.1 / Value 41.1 / Sentiment 54.9
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$55.13M
Beta
1.91
Shares Out
91.88M
P/E (TTM) · Derived
-1.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.72
Rev YoY
-
EPS YoY
+89.6%
Gross Margin
-
Op Margin
-
Net Debt
-$65.88M
Current Ratio
8.92
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology